Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Richard Burack

Showing results (41-50 of 59) with videos related to

Pageof 6
Sort By:
Plos One|May 27, 2016
Follicular Lymphoma Tregs Have a Distinct Transcription Profile Impacting Their Migration and Retention in the Malignant Lymph NodeHristina Nedelkovska, Alexander F Rosenberg, Shannon P Hilchey, et al.
British Journal of Haematology|April 23, 2014
R-CHOP with iodine-131 tositumomab consolidation for advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0433Jonathan W Friedberg, Joseph M Unger, W Richard Burack, et al.
Blood|August 9, 2011
Follicular lymphoma tumor-infiltrating T-helper (T(H)) cells have the same polyfunctional potential as normal nodal T(H) cells despite skewed differentiationShannon P Hilchey, Alexander F Rosenberg, Ollivier Hyrien, et al.
Molecular and Cellular Biology|April 10, 2002
Kinase suppressor of Ras (KSR) is a scaffold which facilitates mitogen-activated protein kinase activation in vivoAnhCo Nguyen, W Richard Burack, Jeffrey L Stock, et al.
Blood Advances|June 28, 2023
Subclonal TP53 mutations are frequent and predict resistance to radioimmunotherapy in follicular lymphomaW Richard Burack, Hongli Li, Diana Adlowitz, et al.
British Journal of Haematology|October 23, 2015
Phase II trial of R-CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601Brian G Till, Hongli Li, Steven H Bernstein, et al.
The American Journal of Surgical Pathology|May 16, 2022
Nodular Lymphocyte-predominant Hodgkin Lymphoma With Nodular Sclerosis: An Underrecognized Feature Associated With Pattern DSiba El Hussein, Xiaoqiong Wang, Hong Fang, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 22, 2016
Late Relapses After High-dose Chemotherapy and Autologous Stem Cell Transplantation in Patients With Diffuse Large B-cell Lymphoma in the Rituximab EraBradley D Hunter, Megan Herr, Philip J Meacham, et al.
Science (New York, N.Y.)|September 27, 2003
The immunological synapse balances T cell receptor signaling and degradationKyeong-Hee Lee, Aaron R Dinner, Chun Tu, et al.
Haematologica|November 30, 2023
Matching-adjusted indirect comparison from the Lymphoma Epidemiology of Outcomes Consortium for Real World Evidence (LEO CReWE) study to a clinical trial of mosunetuzumab in relapsed or refractory follicular lymphomaMatthew J Maurer, Carla Casulo, Melissa C Larson, et al.
Pageof 6

Showing results (41-50 of 59) with videos related to

Sort By:
Pageof 6
Plos One|May 27, 2016
Follicular Lymphoma Tregs Have a Distinct Transcription Profile Impacting Their Migration and Retention in the Malignant Lymph NodeHristina Nedelkovska, Alexander F Rosenberg, Shannon P Hilchey, et al.
British Journal of Haematology|April 23, 2014
R-CHOP with iodine-131 tositumomab consolidation for advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0433Jonathan W Friedberg, Joseph M Unger, W Richard Burack, et al.
Blood|August 9, 2011
Follicular lymphoma tumor-infiltrating T-helper (T(H)) cells have the same polyfunctional potential as normal nodal T(H) cells despite skewed differentiationShannon P Hilchey, Alexander F Rosenberg, Ollivier Hyrien, et al.
Molecular and Cellular Biology|April 10, 2002
Kinase suppressor of Ras (KSR) is a scaffold which facilitates mitogen-activated protein kinase activation in vivoAnhCo Nguyen, W Richard Burack, Jeffrey L Stock, et al.
Blood Advances|June 28, 2023
Subclonal TP53 mutations are frequent and predict resistance to radioimmunotherapy in follicular lymphomaW Richard Burack, Hongli Li, Diana Adlowitz, et al.
British Journal of Haematology|October 23, 2015
Phase II trial of R-CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601Brian G Till, Hongli Li, Steven H Bernstein, et al.
The American Journal of Surgical Pathology|May 16, 2022
Nodular Lymphocyte-predominant Hodgkin Lymphoma With Nodular Sclerosis: An Underrecognized Feature Associated With Pattern DSiba El Hussein, Xiaoqiong Wang, Hong Fang, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 22, 2016
Late Relapses After High-dose Chemotherapy and Autologous Stem Cell Transplantation in Patients With Diffuse Large B-cell Lymphoma in the Rituximab EraBradley D Hunter, Megan Herr, Philip J Meacham, et al.
Science (New York, N.Y.)|September 27, 2003
The immunological synapse balances T cell receptor signaling and degradationKyeong-Hee Lee, Aaron R Dinner, Chun Tu, et al.
Haematologica|November 30, 2023
Matching-adjusted indirect comparison from the Lymphoma Epidemiology of Outcomes Consortium for Real World Evidence (LEO CReWE) study to a clinical trial of mosunetuzumab in relapsed or refractory follicular lymphomaMatthew J Maurer, Carla Casulo, Melissa C Larson, et al.
Pageof 6